drugset / Trial / NCT01782495
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.
Timeline
- Start
- 2013-02-25
- Primary completion
- 2016-11-02
- Completion
- 2017-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | dasabuvir | Small molecule | 250 mg | — |
| Subject | ombitasvir | Small molecule | 25 mg | — |
| Subject | paritaprevir | Small molecule | 150 mg | — |